Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

CRISPR Therapeutics, Vertex Initiate First Industry-Sponsored Trial – What’s Next?

Sep 06 2018

• By Mandy Jackson

Genetic engineering and gene manipulation concept. Hand is replacing part of a DNA molecule. 3D rendered illustration of DNA.

Related Content

Finance Watch: Lilly Cuts 3,500 Jobs Globally To Drive Growth

Sep 08 2017

Merck Develops 'New And Improved' CRISPR

May 18 2017

Global CRISPR Revolution Gathers Pace, Raising Hopes – And Concerns

Nov 24 2017

Gene Editing: A Powerful, Growing Modality In Regenerative Medicine

Nov 27 2017

KSQ Comes Out Of Stealth Mode With $76m And Meeker As CEO

Oct 02 2017

Tech Transfer Roundup: Arrakis Gets Penn IP Toward Small Molecule RNA Therapies

Dec 15 2017

Deal Watch: Vertex Selects First Candidate Under CRISPR Gene-Editing Collaboration

Dec 13 2017

J.P. Morgan Notebook Day 4: CRISPR's Not Worried; Theratechnologies' HIV Niche; And Is Moderna's IPO Coming Soon?

Jan 12 2018

Gilead And Novartis Unveil EU Marketing Plans For CAR-T Therapies, But Hurdles Remain

Aug 28 2018

Allergan And Editas Sharpen Their CRISPR Focus On Ocular Drugs

Aug 07 2018

Exonics Using CRISPR To Develop One-Time Treatment for Duchenne

Feb 28 2017

Bayer And CRISPR Form Cutting Edge Gene Editing JV

Dec 22 2015

Gene Editing Deal Broadens Vertex's CF Base, Doubles CRISPR's Cash

Oct 27 2015

Precision BioSciences Says Baxalta's IO Focus Made It Preferred Partner

Mar 04 2016

China Surprises With First CRISPR Trial Despite Regulatory Lag, Concerns

Jul 26 2016

Can CRISPR Make The Jump To Therapeutics?

Mar 20 2014

Intellia Plans IPO, Signs Gene-Editing Pact With Regeneron

Apr 13 2016

Scrip's Rough Guide To CRISPR Gene Editing

Jun 28 2016

IPO Update: Values Slip As Four More Biopharma Firms Go Public In October

Nov 07 2016

Agenovir: Using Gene Editing To Kill Viral DNA

Aug 15 2017

Juno Looks To Move CAR-T To Solid Tumors Via Editas Deal

May 27 2015

Sangamo Data Is A Moment For Gene Editing, But Leaves Questions

Sep 05 2018

Servier's Shire Oncology Buy Gives Base For US Expansion

Apr 17 2018

UC's CRISPR Licensees Unbowed By Losing Initial US Patent Office Ruling

Feb 16 2017

J.P. Morgan Notebook Day 3: Novartis' Cancer Reorg, AbbVie's Price Pledge, Genentech’s Partnering And More

Jan 12 2017

Related Companies

CRISPR Therapeutics AG

Vertex Pharmaceuticals Incorporated

Bayer AG

Casebia Therapeutics

Editas Medicine

Allergan plc

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Intellia Therapeutics, Inc.

Regeneron Pharmaceuticals, Inc.

Novartis AG

Excision BioTherapeutics Inc.

University of California, Berkeley

Exonics Therapeutics, Inc.

KSQ Therapeutics

Agenovir Corporation

Vir Biotechnology, Inc.

Merck KGaA

MaxCyte, Inc.

Sangamo Therapeutics, Inc.

Gilead Sciences, Inc.

Cellectis SA

Les Laboratoires Servier

Pfizer Inc.

Allogene Therapeutics Inc.

Additional Topics

Clinical Trials Platform Technologies Regenerative Medicine Research & Development BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window